Johnson & Johnson buys Ollin for $2.2 billion in eye disease push

Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, adding a Phase 3 eye antibody for wet AMD and diabetic macular edema, with Blackstone paying $750 million to fund the drug's late-stage trials.

AI illustration for this news story: Johnson & Johnson buys Ollin for $2.2 billion in eye disease push
AI-generated illustration, not a photo.

The deal

Johnson & Johnson announced on Monday it has entered into a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately $1.125 billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.

At the maximum value, the deal would be worth about $3.3 billion. Ollin is a privately held company founded in 2023, and Goldman Sachs acted as lead financial advisor to Ollin, alongside Centerview Partners. Johnson & Johnson described the acquisition as adding a late-stage bispecific antibody with best-in-class potential in ophthalmology.

What OLN324 is

The acquisition centers on OLN324, an investigational Phase 3 bispecific antibody designed to target two key pathways in retinal disease: vascular endothelial growth factor, known as VEGF, and angiopoietin-2, known as Ang2. It is a next-generation antibody with high Ang2 potency and a small protein format, called a minibody, that could enable improved control of retinal fluid.

OLN324 is being developed for wet age-related macular degeneration and diabetic macular edema, two serious retinal diseases affecting more than 40 million people worldwide and among the leading causes of vision loss. The drug was discovered by Innovent Biologics, which developed it with Ollin under the code IBI324, and Ollin has reported proof-of-concept clinical data suggesting it could improve retinal anatomy, although the therapy remains investigational.

The deal at a glanceSource: Reuters
  • Upfront cash$2.2 billion
  • Milestone paymentsUp to about $1.125 billion
  • Maximum total valueAbout $3.3 billion
  • Blackstone Phase 3 funding$750 million
  • People affected by the diseasesMore than 40 million
  • Retinal therapeutics marketAbout $15 billion

Blackstone pays for Phase 3

Separately, and contingent on the acquisition closing, Johnson & Johnson will enter into a development funding agreement with Blackstone Life Sciences. Blackstone will pay a total of $750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324, in exchange for regulatory and sales milestones and single-digit royalties.

The structure is unusual: J&J buys the company, while an outside investor covers the full cost of the expensive late-stage trials. For J&J, it lowers the cash risk of a program that still has to prove itself in Phase 3; for Blackstone, it is a bet that a drug aimed at a large eye disease market will pay off through milestones and royalties.

Close-up of a human eye with a soft blue clinical glow
AI-generated illustration, not a photo.

Why J&J is buying

The deal comes after Johnson & Johnson weathered a pair of gene therapy setbacks in ophthalmology this year, and it rebuilds the company's eye pipeline around a different kind of medicine. Ollin was established to develop next-generation treatments in the global retinal therapeutics market, which its co-founder Paul Berns valued at approximately $15 billion.

That market is dominated by drugs that block VEGF, and OLN324's pitch is to block a second pathway, Ang2, at the same time, in a smaller molecule designed to work better in the eye. Whether that design translates into better vision for patients is what the funded Phase 3 trials will now test. This article is general market commentary, not investment advice.

Sources

Educational content, not investment advice. Facts as of the publish time above; figures come from the linked sources and markets change quickly. Genexus Alpha is not a registered investment adviser or broker.